US Pharma MarketingThe post First healthy volunteers dosed in Bionyra’s Phase I BYN-001 study appeared first on Clinical Trials Arena.
First healthy volunteers dosed in Bionyra’s Phase I BYN-001 study
Bionyra Pharma has dosed the first healthy volunteers in a Phase I trial of BYN-001, its long-acting anti-IL-25 monoclonal antibody. The study will assess the tolerability, safety, pharmacodynamics and pharmacokinetics in healthy individuals. The antibody is being developed for the treatment of atopic dermatitis. Credit: Kwangmoozaa/Shutterstock.com. Bionyra Pharma has dosed the first healthy volunteers in a Phase I trial of BYN-001, its long-acting anti-IL-25 monoclonal antibody, which is being developed for the treatment of atopic dermatitis. The company confirmed the launch of the study in Australia, where the first group of participants is enrolled in the single ascending dose segment…
Bionyra Pharma has dosed the first healthy volunteers in a Phase I trial of BYN-001, its long-acting anti-IL-25 monoclonal antibody.
Source: Clinical Trials Arena